CN101679405A - 作为葡萄糖激酶活性剂的2-氨基吡啶类似物 - Google Patents

作为葡萄糖激酶活性剂的2-氨基吡啶类似物 Download PDF

Info

Publication number
CN101679405A
CN101679405A CN200880017007A CN200880017007A CN101679405A CN 101679405 A CN101679405 A CN 101679405A CN 200880017007 A CN200880017007 A CN 200880017007A CN 200880017007 A CN200880017007 A CN 200880017007A CN 101679405 A CN101679405 A CN 101679405A
Authority
CN
China
Prior art keywords
alkyl
compound
formula
pyridin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880017007A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·D·艾彻
史蒂文·A·博伊德
马克·J·齐卡雷利
凯文·R·康德罗斯基
罗纳德·J·欣克林
阿杰伊·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/007444 external-priority patent/WO2007117381A2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN101679405A publication Critical patent/CN101679405A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
CN200880017007A 2007-03-23 2008-03-19 作为葡萄糖激酶活性剂的2-氨基吡啶类似物 Pending CN101679405A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US91971907P 2007-03-23 2007-03-23
PCT/US2007/007444 WO2007117381A2 (en) 2006-03-24 2007-03-23 2 -aminopyridine analogs as glucokinase activators
US60/919,719 2007-03-23
USPCT/US2007/007444 2007-03-23
US97426007P 2007-09-21 2007-09-21
US60/974,260 2007-09-21
PCT/US2008/057543 WO2008118718A2 (en) 2007-03-23 2008-03-19 2-aminopyridine analogs as glucokinase activators

Publications (1)

Publication Number Publication Date
CN101679405A true CN101679405A (zh) 2010-03-24

Family

ID=39711955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880017007A Pending CN101679405A (zh) 2007-03-23 2008-03-19 作为葡萄糖激酶活性剂的2-氨基吡啶类似物

Country Status (7)

Country Link
US (1) US8362037B2 (enExample)
EP (1) EP2173745A2 (enExample)
JP (1) JP5450108B2 (enExample)
CN (1) CN101679405A (enExample)
CA (1) CA2681695A1 (enExample)
TW (1) TW200843765A (enExample)
WO (1) WO2008118718A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349159A (zh) * 2016-08-29 2017-01-25 山东省联合农药工业有限公司 一种3‑氯‑2‑氰基‑5‑三氟甲基吡啶的制备方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431713B2 (en) * 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
UA101166C2 (ru) 2007-09-21 2013-03-11 Аррей Биофарма Инк. Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
EA201000561A1 (ru) * 2007-10-09 2010-10-29 Мерк Патент Гмбх Производные пиридина, пригодные в качестве активаторов глюкокиназы
JP5529044B2 (ja) * 2008-01-25 2014-06-25 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環化合物
AR077821A1 (es) * 2009-08-11 2011-09-28 Sanofi Aventis Us Llc Procedimiento para preparar hidrocloruro de 4-metil-3-tienilamina
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9296735B2 (en) 2012-05-18 2016-03-29 Amgen Inc. Method for the preparation of thiadiazoles
US9663536B2 (en) 2013-03-13 2017-05-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
AU2015237253B2 (en) 2014-03-28 2019-11-14 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
CN107286087B (zh) * 2017-04-16 2020-01-07 内蒙古佳瑞米精细化工有限公司 一种2-氰基-3-氯-5-三氟甲基吡啶的合成方法
MY208313A (en) 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury
EP3703675A4 (en) 2017-10-30 2021-06-16 Neuropore Therapies, Inc. SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP7648027B2 (ja) 2019-12-19 2025-03-18 クリア、スペイン、エセ、ア、ウ ウパダシチニブの調製のための方法及び中間体
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
TW202315621A (zh) 2021-08-25 2023-04-16 美商皮克醫療公司 Ｅｉｆ４ｅ抑制劑及其用途
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
US20250340570A1 (en) 2022-04-27 2025-11-06 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3703435A1 (de) * 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US7629362B2 (en) * 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
AR049418A1 (es) * 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
ATE521608T1 (de) * 2005-11-01 2011-09-15 Array Biopharma Inc Glucokinaseaktivatoren
ES2378704T3 (es) * 2006-01-27 2012-04-17 Array Biopharma, Inc. Activadores de la glucocinasa
EP2543667B1 (en) * 2006-03-24 2015-01-28 Array Biopharma, Inc. A method of preparing 2-aminopyridine analogs as glucokinase activators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349159A (zh) * 2016-08-29 2017-01-25 山东省联合农药工业有限公司 一种3‑氯‑2‑氰基‑5‑三氟甲基吡啶的制备方法
CN106349159B (zh) * 2016-08-29 2019-03-22 山东省联合农药工业有限公司 一种3-氯-2-氰基-5-三氟甲基吡啶的制备方法

Also Published As

Publication number Publication date
TW200843765A (en) 2008-11-16
JP2010527911A (ja) 2010-08-19
WO2008118718A3 (en) 2008-11-13
JP5450108B2 (ja) 2014-03-26
US8362037B2 (en) 2013-01-29
WO2008118718A2 (en) 2008-10-02
CA2681695A1 (en) 2008-10-02
EP2173745A2 (en) 2010-04-14
US20100105659A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
JP5450108B2 (ja) グルコキナーゼ活性化剤としての２−アミノピリジン類似体
JP2010527911A5 (enExample)
CN105814046B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814047B (zh) 作为tnf活性调节剂的稠合三环咪唑衍生物
JP6495915B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合イミダゾール及びピラゾール誘導体
KR101566042B1 (ko) 진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체
CN105829307B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN105814048B (zh) 作为tnf活性调节剂的稠合三环苯并咪唑衍生物
CN101687827B (zh) 环状基团取代的氨基二氢噻嗪衍生物
CN105814052B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
ES2378704T3 (es) Activadores de la glucocinasa
CN101437816B (zh) 作为葡萄糖激酶活性剂的2-氨基吡啶类似物
TW202302581A (zh) Ｇｌｐ－１ｒ調節化合物
EP2665724A1 (en) Bicyclic inhibitors of alk
CN105814049A (zh) 作为tnf活性调节剂的稠合三环咪唑衍生物
KR20050065670A (ko) 항감염제
JP2010518014A (ja) キナーゼ阻害剤として有用な２−アミノピリジン誘導体
TW200902527A (en) 2-aminopyridine analogs as glucokinase activators
EP4479380A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
TW202340181A (zh) 雜環化合物及其用途
CN107690434B (zh) 作为tnf活性调节剂的稠合三环咪唑并吡嗪衍生物
CN121986099A (zh) 半饱和二环衍生物和相关用途
CN105026393A (zh) Cdk9激酶抑制剂
SG11202108648TA (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
CN103140490A (zh) 氮杂吲唑化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100324